NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01779206,ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer,https://clinicaltrials.gov/study/NCT01779206,ADAPT,COMPLETED,Trial for the optimization of risk assessment and therapy success prediction in patients with early breast cancer by the use of biomarkers in advance to therapy decision-making to personalize therapies.,NO,Breast Cancer,DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Paclitaxel,"Identification of a responder sub-population with intermediate and high risk, which due to therapy has outcome comparable to HR+/RS≤11, 3 Years","Overall survival, 3 Years",,West German Study Group,,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,4936,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,WSG-AM06 / ADAPT HR+/HER2-,2012-05,2019-09,2025-01-15,2013-01-30,,2025-04-08,"Breast Center of the University of Munich (LMU) Universitätsfrauenklinik Großhadern, Munich, Bavaria, 81377, Germany|Ev. Krankenhaus Bethesda Brustzentrum Niederrhein, Mönchengladbach, NRW, 41061, Germany",
